Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$22.74 USD
-5.72 (-20.10%)
Updated Jul 2, 2024 04:00 PM ET
After-Market: $22.73 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Pacira (PCRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$43.56 | $57.00 | $36.00 | 53.06% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Pacira comes to $43.56. The forecasts range from a low of $36.00 to a high of $57.00. The average price target represents an increase of 53.06% from the last closing price of $28.46.
Analyst Price Targets (9 )
Broker Rating
Pacira currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.30 a month ago based on 10 recommendations.
Of the nine recommendations deriving the current ABR, six are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 66.67% and 33.33% of all recommendations. A month ago, Strong Buy made up 70%, while Buy represented 30%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/PCRX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 7 | 7 | 7 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.30 | 1.30 | 1.30 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/7/2024 | Raymond James | Gary Nachman | Moderate Buy | Moderate Buy |
5/7/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
3/4/2024 | H.C. Wainwright & Co. | Oren Livnat | Strong Buy | Strong Buy |
3/1/2024 | Truist Securities | Leszek Sulewski | Strong Buy | Strong Buy |
3/1/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
3/1/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 9 |
Average Target Price | $43.56 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 104 of 252 |
Current Quarter EPS Est: | 0.73 |